Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <> genotype.
Soria, A., Fava, M., Bernasconi, D., Lapadula, G., Colella, E., Valsecchi, M., et al. (2020). Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. LIVER INTERNATIONAL, 40(4), 769-777.
|Citazione:||Soria, A., Fava, M., Bernasconi, D., Lapadula, G., Colella, E., Valsecchi, M., et al. (2020). Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. LIVER INTERNATIONAL, 40(4), 769-777.|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort|
|Autori:||Soria, A; Fava, M; Bernasconi, D; Lapadula, G; Colella, E; Valsecchi, M; Migliorino, G; D'Ambrosio, R; Landonio, S; Schiavini, M; Spinetti, A; Carriero, C; Degasperi, E; Cologni, G; Gatti, F; Vigano, P; Hasson, H; Uberti-Foppa, C; Pasulo, L; Baiguera, C; Rossotti, R; Vinci, M; Puoti, M; Giorgini, A; Menzaghi, B; Lombardi, A; Pan, A; Aghemo, A; Grossi, P; Boldizzoni, R; Colombo, S; Vigano, M; Rumi, M; Del Poggio, P; Valenti, L; Giglio, O; De Bona, A; d'Arminio Monforte, A; Colombo, A; Spinelli, O; Pigozzi, M; Molteni, C; Bonfanti, P; Terreni, N; Perini, P; Capretti, A; Bella, D; Liani, C; Polo, S; Aimo, G; Pagnucco, L; Bhoori, S; Centenaro, R; Graffeo, M; Ciaccio, A; Dionigi, E; Lazzaroni, S; Carderi, I; Di Marco, M; Rizzardini, G; Noventa, F; Lampertico, P; Fagiuoli, S|
SORIA, ALESSANDRO (Corresponding)
|Data di pubblicazione:||2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/liv.14386|
|Appare nelle tipologie:||01 - Articolo su rivista|